Nowadays, steroids and anti-VEGF are the first line treatment for diabetic macular edema.
Ozurdex is the most frequently used steroid and has label for both first and second line
treatment. Ozurdex treatment paradigm for patients with diabetic macular edema is to inject
patient only in case of huge recurrence. The risk of this scheme is a progressive loss of
vision due to photoreceptors loss. A more pro-active regimen, as it already exists for
anti-VEGF treatment, would allow a better patient management. A new treatment paradigm
consisting in a loading dose of 2 injections within 3 months, followed by a PRN (Pro Re Nata)
regimen with strict retreatment criteria and minimal time limit of 3 months between two
injections should result in a better visual acuity gain and a limited augmentation of the
number of injections (which will remain lower than the number observed for anti-VEGF
The investigators have therefore chosen a pilot study to investigate the impact on efficacy
and on the number of intravitreal injections (IVI) of such a scheme.
Diabetic Macular Edema
Dexamethasone with 2 loading doses followed by PRN regimen.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.